Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 202-049-5 | CAS number: 91-20-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
NOAEC(inhal.) of 5 mg/m3 could be identified for local respiratory effects from a 90d study.
The NOAEC(90 d) for systemic respiratory effects was 300 mg/m3 (highest concentration tested).
By the dermal route, a NOAEL for systemic toxicity of 1000 mg/kg/day (the highest dose tested) has been identified in a 90-day rat study. Slight changes at the treated skin site were noted.
By the oral route, NOAELs in rat and mice for systemic effects were 200 mg/kg bw/d, based on the absence of histopathologic changes; however, based on unspecific clinical effects, the NOAELs came down to 100 mg/kg/day.(considered a NOEL)
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1980
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Study following accepted scientific standards; although no guideline provided, acceptable for assessment.
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 408 (Repeated Dose 90-Day Oral Toxicity Study in Rodents)
- Deviations:
- yes
- Remarks:
- no documentation of organ weights
- GLP compliance:
- no
- Limit test:
- no
- Species:
- rat
- Strain:
- Fischer 344
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River, Portage, Michigan
- Age at study initiation: 6 weeks
- Weight at study initiation: Males: 170 - 215 g; females: 135-155 g
- Fasting period before study: no data
- Housing: groups of 5 animals per polycarbonate cages
- Diet (e.g. ad libitum): yes (added as needed)
- Water (e.g. ad libitum): yes (via automatic watering devices)
- Acclimation period: 15 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21 - 23 °C
- Humidity (%): 40 - 60 % relative humidity
- Air changes (per hr): 15
- Photoperiod (hrs dark / hrs light): 12 / 12 - Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:
Stock solution was prepared by placing a weighed portion of naphthalene into a mixing graduated cylinder and adding corn oil to make up the proper volume. Selected doses of 400, 200, 100, 50 and 25 mg/kg were achieved by preparing a stock solution of the highest concentration and sequential dilution in order to reach the appropriate dose level. The respective mixture quantities were prepared on a weekly basis.
VEHICLE
- Justification for use and choice of vehicle (if other than water): no justification provided
- Concentration in vehicle: 400, 200, 100, 50, 25 mg/5 mL solution
- Amount of vehicle (if gavage): 0.5 mL solution per 100 g body weight - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- One analysis for the accuracy of the dose was performed: results were within +/- 10% of the concentrations for all dose levels, except 200 mg/kg which had a deviation of 1.76 % from this range.
- Duration of treatment / exposure:
- 13 weeks
- Frequency of treatment:
- 1x/d, five consecutive days per week.
- Remarks:
- Doses / Concentrations:
25, 50, 100, 200, 400 mg/kg bw
Basis:
actual ingested - No. of animals per sex per dose:
- Ten animals of each sex per dose level.
- Control animals:
- yes, concurrent no treatment
- Details on study design:
- - Dose selection rationale: Dose selection was performed in order to determine maximum tolerated doses for a subsequent 104-week chronic toxicity study. Dose selections for this sub-chronic study were based on clinical and pathological findings which were observed during a prior two-week repeated dose study.
- Other: Animals were administered 5 ml/kg bw with the respective mixture. - Positive control:
- no
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: twice each day (with at least six hours between observation)
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: twice each day (with at least six hours between observation)
BODY WEIGHT: Yes
- Time schedule for examinations: weekly - Sacrifice and pathology:
- Detailed necropsy examinations were performed on all rats in this study. The following tissues were examined: mandibular lymph node, salivary gland, femur, thyroid, parathyroid, small intestine, colon, liver, prostate, testes, ovaries, lungs and mainstem brochi, mammary gland, eyes, heart, oesophagus, stomach, uterus, brain (3 sections), thymus, trachea, pancreas, spleen, kidneys, adrenals, urinary bladder, pituitary gland.
For histopathology, the tissues obtained from the highest dosage groups and from the control group were examined in a routine manner: they were sectioned at 5 µm, stained with haematoxylin and eosin and examined microscopically.
Since lesions had been observed in the highest dosage groups, which may have been substance-specific, kidneys from males and thymus glands from females were examined from the 200 mg/kg dosage groups. - Other examinations:
- Haematology
- Statistics:
- Yes (in regard of body weight and haematology)
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Signs of discomfort and disorder observed in the highest dosage groups of both sexes. 2/10 males died during the last week of the study.
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- Signs of discomfort and disorder observed in the highest dosage groups of both sexes. 2/10 males died during the last week of the study.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Dose-related trend especially at the two highest doses.
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- no effects observed
- Ophthalmological findings:
- not specified
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Marginal decrease in haemoglobin and haematocrit at 400 mg/kg bw in the male and female group.
- Clinical biochemistry findings:
- not specified
- Urinalysis findings:
- not specified
- Behaviour (functional findings):
- not specified
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Lesions in kidneys (male rats) and thymus glands (female rats) were observed at highest dosage groups.
- Histopathological findings: neoplastic:
- no effects observed
- Details on results:
- CLINICAL SIGNS AND MORTALITY:
Diarrhoea, lethargy, hunched posture and roughened haircoats were observed in animals of both sexes of the highest dosage groups. Mortality was noted for two male rats in the highest dose groups in the last week of the experiment. In one of the dead animals, renal lesions were found.
BODY WEIGHT AND FOOD CONSUMPTION:
Effects on body weights were observed at the 400 mg/kg and 200 mg/kg dose groups: in male rats significant decreases in body weight of -60% and -24% were seen in the 400 mg/kg and 200 mg/kg dose groups, respectively. In female rats, both doses caused a decrease in body weight of -69% and -15%, respectively. No substance-specific trends in diet consumption were evident.
HAEMATOLOGY
Marginal decrease in haemoglobin and haematocrit in the male and female group of 400 mg/kg bw. Considerable effects on lymphocyte and neutrophil values were observed in males of the highest dosage groups (400 mg/kg bw).
HISTOPATHOLOGY:
Lesions in kidneys from male animals (score 3 = moderate) and thymus glands from female animals (score 3 = moderate) have been observed in the highest dosage groups (400 mg/kg bw). - Dose descriptor:
- NOEL
- Effect level:
- 100 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: based on decrease in body-weight gain
- Dose descriptor:
- NOAEL
- Effect level:
- 200 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: based on clinical signs, mortality (males), haematological effect, and some evidence of histological changes (kidney, thymus).
- Dose descriptor:
- LOAEL
- Effect level:
- 400 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Critical effects observed:
- not specified
- Conclusions:
- After 13 weeks of oral exposure by gavage, unspecific adverse effects, predominantly loss in body-weight gain, considered to be substance-related were noted from 200 mg/kg bw/d onwards.
- Executive summary:
Doses of 0, 25, 50, 100, 200, and 400 mg naphthalene/kg bw/d were administered orally in corn oil to Fischer 344 rats (60 rats per sex) for five days a week for 13 weeks. Up to 200 mg/kg bw/d, the only signs - obviously substance-related - were decrease in body weight of >10 % in both sexes. At 400 mg/kg bw/d, in addition, clear clinical signs of discomfort and disorder (lethargy, roughened haircoats, hunched posture, and diarrhoea) emerged, but also mortality was slightly increased (2/10 males during the last week of the study, one with renal lesion), shifts in the lymphocyte count and apparently an increasing trend in organ damage (kidney in males and there noted, and the thymus) were observed.
Reference
Table 1: Summary of necropsy data by group and sex Note: Only organs that exhibited anomalies in any group have been documented.
|
Table 2: Summary of histopathology data by group and sex Note: Only organs that exhibited anomalies in any group have been documented.
# 200 mg/kg bw: Unscheduled histopathology only of kidney (males) and thymus (females) examined due to increased effect at 400 mg/kg bw.
|
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 200 mg/kg bw/day
- Study duration:
- subchronic
- Species:
- rat
- Quality of whole database:
- acceptable, NOAEL based on histopathological observations, also corresponds to the NOAEL in mice.
Repeated dose toxicity: inhalation - systemic effects
Link to relevant study records
- Endpoint:
- sub-chronic toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1993
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP study performed according to EPA and OECD guideline.
- Qualifier:
- according to guideline
- Guideline:
- EPA OPP 82-4 (90-Day Inhalation Toxicity)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 413 (Subchronic Inhalation Toxicity: 90-Day Study)
- Deviations:
- yes
- Remarks:
- no recovery groups included, histopathology only for respiratory tract
- GLP compliance:
- yes
- Limit test:
- no
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- SOURCE:
- Age at study initiation: 8 ½ weeks
- Weight at study initiation: Male 221 – 272g; female 155 – 190g
- Fasting period before study: None
- Housing: Group housed 5/sex/cage
- Diet: ad libitum (while in cages)
- Water: ad libitum
- Acclimation period: 18 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 18 – 22°C
- Humidity (%): 30 – 67
- Air changes (per hr): Not provided
- Photoperiod (hrs dark / hrs light): 12 hr dark / 12 hr light - Route of administration:
- inhalation: vapour
- Type of inhalation exposure:
- nose only
- Vehicle:
- clean air
- Remarks on MMAD:
- MMAD / GSD: Not applicable; vapour
- Details on inhalation exposure:
- GENERATION OF TEST ATMOSPHERE / CHAMBER DESCRIPTION:
-Exposure apparatus: Nose only inhalation chamber (ADG Instruments) with 20 exposure ports and a top section incorporating a tangential air inlet.Each chamber was assembled in 3 sections and formed a 28 cm diameter cylinder with a volume of approximately 50 litres. A separate exposure chamber was used for each group.
- Method of holding animals in test chamber: Molded polycarbonate tubes tapered at one end to allow the nose-only of the rat to protrude from the tapered end of the chamber. The other end was closed by insertion of an expanded plastic bung.
- Source and rate of air: Air was withdrawn from the base of the chamber at a rate of 30 litres/minute. The air was withdrawn by a vacuum pump through filtration media, to remove particulate, and a silica gel to remove excess moisture. The air supply to the chamber was comprised of a carrier (vapour) and a diluent air supply, to a total of 25 litres/minute to allow the exposure chamber to be maintained at a slight negative pressure.
- Method of conditioning air: See above
- System of generating particulates/aerosols: A separate vapour generation system was used for each group. It consisted of a 3-necked round bottom flask containing an aliquot of the test substance. Air was passed through the flask and vapour-laden air passed out through a second neck. The third neck contained a thermometer. At lower concentrations the test atmosphere was generated under ambient temperatures using the carrier airflow to maintain the concentration. At higher concentrations the test substance flask and carrier air was heated in a water bath to assist vaporisation. The vapour-laden air was passed through a clear plastic tube with glass wool (particulate trap) and mixed with diluent air (where applicable) before entering the chamber.
- Temperature, humidity, pressure in air chamber: Temperature 19.7 – 20.1°C; Humidity 45 – 52%; Oxygen concentration 21%
- Air flow rate: 30 litres/minute
- Air change rate: (30 l/min)/50 l; 36/hour
- Method of particle size determination: Not applicable
TEST ATMOSPHERE:
- Brief description of analytical method used: GC analysis of samples reacted with carbon disulfide. Column: 2mm x 1m i.d. glass packed with 10% OV-101 (80 -100 mesh). Column conditions: temperature- injector 200°C, column 120°C, detector 250°C. Gases: helium 30ml/min, hydrogen 33 ml/min, air 300ml/min: Retention time for Naphthalene 1.3 minutes.
- Samples taken from breathing zone: Yes
VEHICLE (if applicable):
- Justification for use and choice of vehicle: Air; Not applicable - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Samples taken at 1, 3 and 5 hours for all treatment groups during each exposure.
Brief description of analytical method used: GC analysis of samples reacted with carbon disulfide. Column: 2mm x 1m i.d. glass packed with 10% OV-101 (80 -100 mesh). Column conditions: temperature- injector 200°C, column 120°C, detector 250°C. Gases: helium 30ml/min, hydrogen 33 ml/min, air 300ml/min: Retention time for Naphthalene 1.3 minutes.
Samples taken from breathing zone: Yes - Duration of treatment / exposure:
- 13 consecutive weeks
- Frequency of treatment:
- Six hours exposure for 5 days a week
- Remarks:
- Doses / Concentrations:
Target 2, 10, 60 ppm: analysed 2, 10, 58 ppm (11, 51, and 304 mg/m3)
Basis:
analytical conc. - No. of animals per sex per dose:
- 10/sex/dose
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- Dose selection rationale: 4 week inhalation study
Rationale for animal assignment (if not random): Computer distribution based on body weight
Rationale for selecting satellite groups: None - Positive control:
- none
- Observations and examinations performed and frequency:
- Observations and examinations performed and frequency
CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Twice a day
- Cage side observations checked in table [No. 9.1] were included.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Weekly
BODY WEIGHT: Yes
- Time schedule for examinations: Weekly
FOOD CONSUMPTION:
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes, Weekly
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: Not calculated but data present
WATER CONSUMPTION: No
OPHTHALMOSCOPIC EXAMINATION: Yes
- Time schedule for examinations: Prior to allocation and during week 13
- Dose groups that were examined: All
HAEMATOLOGY: Yes
- Time schedule for collection of blood: Week 13
- Anaesthetic used for blood collection: Yes, light ether anaesthesia
- Animals fasted: Yes
- How many animals: All
- Parameters checked in table [No. 9.7] were examined. PCV, Hb, RBC, MCHC, MCV, WBC, Diff, Plts, TT, Retic, and P, H, A, and R.
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: Week 13
- Animals fasted: Yes
- How many animals: All
- Parameters checked in table [No. 9.8] were examined. CPK, Glucose, GPT, GOT, g-GT, AP, total protein, Alb, Glob, Urea Nitr, Total bilirubin, Creatine, NA, K, Ca, P, Cl, and Chol.
URINALYSIS: No
NEUROBEHAVIOURAL EXAMINATION: No - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
HISTOPATHOLOGY: Yes - Statistics:
- Bartlett’s for homogeneity, if heterogeneous then Kruskal-Wallis. Analysis of variance (Student’s t test) for dose response.
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- 3 deaths but not related to treatment. Increase in brown staining of fur but not considered toxicologically significant.
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- 3 deaths but not related to treatment. Increase in brown staining of fur but not considered toxicologically significant.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Reduced body weight gain at 58 ppm in males and females. Reduced body weight gain at 10 ppm in males.
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- Reduced food consumption at 10 and 58 ppm in males. Reduced food consumption at 58 ppm in females (not statistically significant).
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- no effects observed
- Haematological findings:
- no effects observed
- Description (incidence and severity):
- Lymphocyte and total WBC were reduced in male rats, not considered treatment-related, as the control values were found at the high end of the normal range.
- Clinical biochemistry findings:
- no effects observed
- Description (incidence and severity):
- All differences were inconsistent between sexes, not dose-related and therefore not considered to be of toxicological significance.
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Description (incidence and severity):
- A decrease in absolute liver weight but increase in relative liver weight to body weight only in high-dose males. In the absence of microscopic changes, it was considered unlikely to be of toxicological significance.
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Stained body fur at 10 and 58 ppm. Could be the result of method of restraint used.
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- See "details on results".
- Histopathological findings: neoplastic:
- no effects observed
- Details on results:
- Histopathology non-neoplastic:
Degenerative changes in the olfactory epithelium including slight disorganisation, occasional degenerated cells, atrophy and erosion. The changes were more severe at 10 and 58 ppm and generally less severe at mild grades of individual lesions at 2 ppm. Also subepithelial effects were observed in Bowman’s glands at all exposure levels.
Proliferative lesions of the olfactory epithelium at the 58 ppm dose included hyperplasia of basal cells, rosette formation, hyperplasia (with loss of olfactory features), and in a single case early squamous metaplasia. The dose response of the proliferative lesions were not so obvious as of the degenerative changes due to the fact that continuous degenerative damage at the 60 ppm level resulted in increased cell death, thus restricting the proliferative (reparatory) changes. - Dose descriptor:
- NOAEC
- Remarks:
- for nasal inflammation
- Remarks on result:
- not determinable
- Remarks:
- no NOAEC identified
- Dose descriptor:
- NOAEL
- Remarks:
- for systemic effects
- Effect level:
- ca. 300 mg/m³ air
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: no direct database for this endpoint, however conclusive In synopsis with results from carcinogenicity (see there) and oral repeated-dose studies.
- Remarks on result:
- not determinable
- Remarks:
- no NOAEL identified
- Dose descriptor:
- LOAEC
- Effect level:
- 0.011 mg/L air (analytical)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Histopathology: local degenerative effects in the olfactory region - atrophy, hyperplasia of epithelium, loss of Bowman´s glands
- Dose descriptor:
- LOAEC
- Effect level:
- 2 ppm (analytical)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: see histopathologic effects above
- Critical effects observed:
- not specified
- Conclusions:
- LOAEL 2 ppm based on minor histopathological changes in the nasal epithelium.
- Executive summary:
Rats were exposed to test atmospheres containing naphthalene at concentrations of 2, 10 and 58 ppm. Exposures were 6 hours continuous each day, 5 days a week for 13 weeks.
Statistically significant reduced body weight gain was seen in rats of both sexes exposed to 58 ppm and in male rats exposed to 10 ppm. The reductions in weight gain were associated with reduced food consumption. Body-weight gain and food consumption were also minimally lower than control values for other exposed groups/sexes, but did not reach statistical significance.
Laboratory investigations revealed no evidence of treatment-associated changes or systemic toxicity, and organ-weight analysis and macroscopic findings at necropsy also revealed no adverse changes.
Microscopic examination revealed treatment-related effects on the nasal epithelium at all exposure levels. The severity of the effects was dose-related. At the highest level (58 ppm) changes included erosion of the olfactory epithelium, hyperplasia of basal cells in the olfactory epithelium, loss of Bowman’s glands, hypertrophy of the respiratory epithelium and other inflammatory changes.
At the lowest level of exposure (2 ppm) changes in the olfactory epithelium were less marked but included slight disorganisation, eosinophilic inclusions, occasional degenerate cells, minimal atrophy, minimal erosion (in a single rat), minimal hyperplasia of basal cells, minimal rosette formation, atrophic cells in Bowman’s glands and loss of Bowman’s glands and presence of cysts. In addition dilated gland ducts and squamous metaplasia (in a single rat) were also seen at the low level of exposure (not dose-responsive).
A "No-Effect Level" for the nasal lesions was not established in this study.
Reference
Histological Effects of Naphthalene on Nasal Passages
Nasal passages |
Males (animals affected/10) |
Females (animals affected/10) |
||||||
Dose in ppm |
0 |
2 |
10 |
58 |
0 |
2 |
10 |
58 |
|
|
|
|
|
|
|
|
|
Olfactory epithelium |
||||||||
Slight disorganisation |
0 |
4 |
0 |
0 |
0 |
4 |
0 |
0 |
Eosinophilic inclusions (total) |
0 |
1 |
1 |
2 |
0 |
0 |
2 |
0 |
Minimal |
0 |
1 |
1 |
1 |
0 |
0 |
2 |
0 |
Moderate |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
Occasional degenerate cells (total) |
0 |
4 |
4 |
8 |
0 |
3 |
3 |
8 |
Trace |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
Minimal |
0 |
4 |
2 |
5 |
0 |
3 |
3 |
7 |
Moderate |
0 |
0 |
1 |
3 |
0 |
0 |
0 |
1 |
Atrophy (total) |
0 |
9 |
9 |
10 |
0 |
9 |
10 |
10 |
Trace |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
Minimal |
0 |
8 |
1 |
0 |
0 |
0 |
0 |
0 |
Moderate |
0 |
0 |
8 |
8 |
0 |
0 |
9 |
6 |
Marked |
0 |
0 |
0 |
2 |
0 |
0 |
0 |
4 |
Erosion (total) |
0 |
1 |
4 |
6 |
0 |
0 |
5 |
5 |
Trace |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
1 |
Minimal |
0 |
1 |
2 |
4 |
0 |
0 |
4 |
1 |
Moderate |
0 |
0 |
1 |
2 |
0 |
0 |
1 |
3 |
Hyperplasia of basal cells (total) |
0 |
3 |
8 |
6 |
0 |
6 |
7 |
6 |
Trace |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
Minimal |
0 |
2 |
4 |
4 |
0 |
5 |
6 |
5 |
Moderate |
0 |
1 |
3 |
2 |
0 |
1 |
1 |
1 |
Rosette formation (total) |
0 |
3 |
7 |
4 |
0 |
3 |
7 |
6 |
Trace |
0 |
1 |
0 |
1 |
0 |
1 |
0 |
0 |
Minimal |
0 |
2 |
6 |
2 |
0 |
2 |
6 |
6 |
Moderate |
0 |
0 |
1 |
1 |
0 |
0 |
1 |
0 |
Hyperplasia (total) |
0 |
0 |
0 |
0 |
0 |
2 |
3 |
0 |
Minimal |
0 |
0 |
0 |
0 |
0 |
2 |
3 |
0 |
Early squamous metaplasia - minimal |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
|
|
|
|
|
|
|
|
|
Bowman’s Glands |
||||||||
Atrophic cells |
0 |
1 |
6 |
1 |
0 |
4 |
6 |
5 |
Loss of glands around dorsal meatus |
0 |
5 |
9 |
10 |
0 |
6 |
9 |
10 |
|
|
|
|
|
|
|
|
|
Respiratory epithelium |
||||||||
Dilated gland ducts |
0 |
1 |
3 |
1 |
3 |
1 |
1 |
0 |
Hypertrophy |
0 |
0 |
4 |
10 |
0 |
0 |
6 |
6 |
Squamous metaplasia |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEC
- 300 mg/m³
- Study duration:
- subchronic
- Species:
- rat
- Quality of whole database:
- on its own not evaluable for systemic effects, but see justification of selection.
Repeated dose toxicity: inhalation - local effects
Link to relevant study records
- Endpoint:
- sub-chronic toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP study according to US EPA guideline.
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.3465 (90-Day Inhalation Toxicity)
- Deviations:
- yes
- Remarks:
- Histopathology only for respiratory tract
- GLP compliance:
- yes
- Limit test:
- no
- Species:
- rat
- Strain:
- Fischer 344
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories, Kingston, NY
- Age at study initiation: approx. 6-7 weeks of age on receipt
- Weight at study initiation: no data
- Fasting period before study: none
- Housing: singly housed in stainless steel wire mesh cages (Hazelton inhalation racks, Lab Products, Seaford, DE) in a climate-controlled room
- Diet: pelleted food (NIH-07, Zeigler Bros., Gardners, PA), ad libitum
Food was removed during inhalation exposure
- Water: reverse-osmosis purified; ad libitum
- Acclimation period: Acclimated in the animal facility for approximately two weeks prior to beginning the inhalation exposure - Route of administration:
- inhalation: vapour
- Type of inhalation exposure:
- whole body
- Vehicle:
- other: nitrogen gas as carrier of naphthalene vapour into the exposure chamber
- Remarks on MMAD:
- MMAD / GSD: not applicable (No aerosol or particle formation was observed)
- Details on inhalation exposure:
- GENERATION OF TEST ATMOSPHERE / CHAMBER DESCRIPTION
- Exposure apparatus: 1 m3 whole body exposure chambers (H1000, Lab Products, Seaford, DE) using Hazelton R-24 cage units.
- Method of holding animals in test chamber: One chamber for each concentration including a control chamber
- Source and rate of air: 95% HEPA-filtered
- System of generating particulates/aerosols: Naphthalene vapors were generated by heating solid naphthalene and using nitrogen gas to carry the vapor into the 1 m3 chamber inlet. Concentrations of test substance in the chambers were controlled by adjusting a combination of the heating
temperature and nitrogen flow rate through the generators(see publication p 71 for details).
- Temperature: 73-75 °F; humidity: 45-56 %
- Air flow rate: 300 l/min)
- Air change rate: Approx. 18 air changes per hour
- Method of particle size determination: Prior to and during animal exposures, a check for aerosol formation was conducted.
A scanning mobility particle sizer (SMPS, Model 3934, TSI, Inc., Shoreview, MN) was used to measure particle concentration and size distribution in
the size range from 4 nm to 1000 nm.
- Treatment of exhaust air: no data
TEST ATMOSPHERE
- Brief description of analytical method used: During exposures, naphthalene concentration was measured using a gas chromatograph mass
spectrometer (GC/MS, Model GCMS-QP2010 Plus, Shimadzu, Kyoto, Japan) equipped with a Rxi-5ms 15 m x 0.32 mm id x 0.25 µm film thickness
capillary column and mass spectrometer detection system.
- Samples taken from breathing zone: yes, at 9 locations in the exposure chamber - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Purity check by gas chromatography with flame ionization detector (GC/FID) of the test substance was conducted pre- and post-exposure to check for stability.
- Duration of treatment / exposure:
- 90 d
- Frequency of treatment:
- Animals were exposed to the target concentration for 6h/day, 5d/wk for a total of 65 or 66 exposure days (for approximately a 90-day period).
- Remarks:
- Doses / Concentrations:
0 (control), 0.1, 1.0, 10, 30 ppm
Basis:
nominal conc. - Remarks:
- Doses / Concentrations:
0.00 +-0.00(control); 0.10+-0.00; 0.97+-0.06; 9.97+-1.2; 29.8+-1.7 ppm
Basis:
analytical conc. - No. of animals per sex per dose:
- 10 (additional 5/ sex/ group evaluated for recovery 4wk post-exposure)
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: based on previous investigations
- Rationale for selecting satellite groups: no data
- Post-exposure recovery period in satellite groups: 4 wk - Positive control:
- No
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Twice per day: Observation for mortality and overt clinical signs prior to and immediately following daily exposure.
DETAILED CLINICAL OBSERVATIONS: Yes
BODY WEIGHT: Yes
- Time schedule for examinations: Once per week: Animals were weighed prior to the start of exposures.
ORGAN WEIGHTS: yes (liver, kidneys, adrenals, testes, epididymides, ovaries, uterus, thymus, spleen, brain, and heart)
FOOD CONSUMPTION:
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
(Food and water consumption was measured in a subset of rats assigned as recovery animals (5/sex/group) by transferring animals to
polycarbonate caging following the end of the weekly exposure period)
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight
gain data: No data
WATER CONSUMPTION: Yes
- Time schedule for examinations: see above
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: No
CLINICAL CHEMISTRY: No
URINALYSIS: No
NEUROBEHAVIOURAL EXAMINATION: No - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
HISTOPATHOLOGY: Yes (see table 1 and 2, attached document: only focussed on the head with nasal region: Cross-sectional blocks of the nasal tissues were prepared at 6 levels after preparation.) - Statistics:
- Continuous variables (e.g. body weight, food and water consumption, and organ weights) were analysed using the default statistical method of the Provantis software system (NT2000, versions 8.2.0.1 or 8.2.0.6, Instem/PA). A result of p<0.05 was considered significant.
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Concentration-related decrease at the end of the 90 d study in the 10 and 30 ppm groups.
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- effects observed, treatment-related
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- for absolute but not relative organ weights (see Tab. 3 and 4, below)
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- see tables 1 and 2 (attached documents: only shown for males, similar for females)
- Histopathological findings: neoplastic:
- no effects observed
- Details on results:
- FOOD and WATER CONSUMPTION: Decreased in animals exposed at 30 ppm. The decreased consumption appears to be correlated with the
observed decreased body weights in animals at the higher exposure concentrations of naphthalene.
ORGAN WEIGHTS:
- Males:The absolute mean weights of the spleen, left testis, and thymic region of male rats exposed to 30 ppm were statistically significantly lower
(p< 0.05 or p< 0.01) than the control mean values (Table 3).
Mean right testis weight was slightly lower than control, but not statistically significant.
The magnitude of the organ weight decreases compared to control means was approximately 5% (spleen and left testis) and 17% (thymus).
When expressed relative to body weight, these organ weights were similar to control values (Table 3).
Similar observations were observed in the organ weights of the 10 ppm-exposed males.
- Females: In female rats, the absolute mean weights of the heart, liver, and thymic region were statistically significantly lower (p<0.05 or p< 0.01)
than the control mean weights in all exposed groups (except the heart weight of the 10ppm group, the liver weight of the 1ppm group, and the
thymus weight of the 0.l ppm group) (Table 4). magnitude of these decreases (5-7% for heart and liver; 16% for thymus) was not exposure
concentration-dependent
Relative to body weight, they were similar to control values (Table 4).
A decrease in mean weight of adrenal glands in the l0ppm exposed females only was considered spurious.
- 4-weeks recovery: All statistically significant differences in organ weight values (absolute, relative to body weight or to brain) observed immediately following the 90-day exposure regimen were diminished in magnitude and no longer statistically significantly different from control values
following 4 weeks recovery
HISTOPATHOLOGY: NON-NEOPLASTIC
- Respiratory and olfactory epithelium: Microscopic evaluation showed naphthalene-induced lesions.
Squamous epithelium or transitional/respiratory epithelium: Minimal to slightly mild inflammation of the was observed in the nasal tip and level 1
areas of all exposure groups, including controls (Table 1 for male data). Low grade inflammation was also observed in all exposure groups,
including controls, after a 4 week recovery period (Table 2 for male data). This observation was not considered to be related to exposure.
- Respiratory epithelium: No lesions were observed in animals exposed to 0.1ppm naphthalene. Lesions related to exposure were observed
beginning at level 2 in the nose.
- Transitional/respiratory epithelium: At a concentration of 1ppm, hyperplasia was observed in males and females with an average severity of 1.0
(minimal). The severity of the lesion progressed to mild hyperplasia at l0ppm (average severity 1.4 in males, average severity of 1.6 in females)
and 30 ppm (average severity of 1.4 in males and average severity of 1.5 in females) (Figures 2 and 3; Table 1 for male data).
Minimal squamous metaplasia of the transitional/respiratory epithelium was also observed in level 2 sections of male and female nasal cavities
with average severity of 0.9 and 0.8 for l0ppm and 30ppm, respectively (Table 1 for male data).
- Olfactory epithelium: Olfactory epithelial degeneration and necrosis was observed at the 10- and 30-ppm exposure concentrations in males and
females (see severity scores: table 1, attached document). Associated with the degenerative olfactory epithelium, there was a prominent basal cell
hyperplasia characterized by an increase in the number of basal cells resulting in thickening of this layer of cells immediately under the
degenerative epithelium (see publication, fig. 6)
The incidence and severity of both the olfactory epithelium degeneration and basal cell hyperplasia lesions decreased in exposed males and females after the 4-week recovery period (Table 2, attached document; publication, fig. 7).
There were no olfactory epithelial effects seen in male or female rats exposed at 0.1 or 1.0ppm (Table 1 for male data). - Dose descriptor:
- NOEC
- Effect level:
- ca. 0.1 ppm (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Histopathology: Absence of lesions in the olfactory and respiratory epithelia
- Dose descriptor:
- NOAEC
- Effect level:
- 1 ppm (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Histopathology: Absence of lesion in the olfactory epithelium, minimal hyperplasia in the repiratory epithelium in all animals, but reversible during recovery period
- Dose descriptor:
- LOAEC
- Effect level:
- 10 ppm
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Histopathology: Clear increase in the frequency of olfactory effects (hyperplasia, degeneration and necrosis) in 6/10 to 10/10 animals (males) graded from minimal to mild, regressing in severity and number within 4-wk recovery but not completely.
- Critical effects observed:
- not specified
- Conclusions:
- No histopathological adverse effects were noted at 0.1 ppm naphthalene: Therefore, this exposure concentration is adopted as NOEC.
Reference
The absolute weights of the spleen, left testis (ca. -5%), and thymic region (ca. -17%) of male rats exposed to 10 or 30 ppm were significantly lower than the control values (see Tab. 3 + 4 below), but no difference was noted for the relative organ-weights.
Mean right testis weight was slightly lower than control without statistical significance.
In females, sporadic decreases in absolute liver, heart, and thymus weight were observed, but when related to body-weight differences disappeared.
Table 3: Select absolute and relative organ weights for male F344 rats immediately following the 90-day study
(from: Dodd et al., 2012)
Organ |
Target exposure concentration (ppm) |
||||
0 |
0.1 |
1.0 |
10 |
30 |
|
Spleen (g) |
0.710 ± 0.039 (a) |
0.709 ± 0.021 |
0.746 ± 0.075 |
0.676 ± 0.034 |
0.670* ± 0.037 |
Spleen (%) (b) |
0.21 ± 0.01 |
0.21 ± 0.01 |
0.22 ± 0.03 |
0.22 ± 0.01 |
0.22 ± 0.01 |
Testis, left (g) |
1.567 ± 0.046 |
1.565 ± 0.041 |
1.535 ± 0.078 |
1.491** ± 0.069 |
1.507* ± 0.046 |
Testis, left (%) |
0.47± 0.02 |
0.47 ± 0.02 |
0.45 ± 0.02 |
0.48 ± 0.04 |
0.49 ± 0.03 |
Thymic region (g) |
0.350 ± 0.074 |
0.319 ± 0.038 |
0.340 ± 0.064 |
0.291* ± 0.035 |
0.289* ± 0.039 |
Thymic region (%) |
0.ll ± 0.02 |
0.10 ± 0.01 |
0.10 ± 0.02 |
0.09 ± 0.01 |
0.09 ± 0.01 |
(a) Mean ± standard deviation for n =10,
(b) Percentage of body weight,
* p<0.05 compared to control,
** p<0.01 compared to control
Table 4: Select absolute and relative organ weights for female F344 rats immediately following the 90-day study
(from: Dodd et al., 2012)
Organ |
Target exposure concentration (ppm) |
||||
0 |
0.1 |
1.0 |
10 |
30 |
|
Heart (g) |
0.595 ±0.018 (a) |
0.562* ± 0.036 |
0.559* ± 0.041 |
0.570 ± 0.040 |
0.564* ± 0.017 |
Heart (%) (b) |
0.31 ± 0.02 |
0.31 ± 0.02 |
0.30 ± 0.02 |
0.31 ± 0.02 |
0.31 ± 0.02 |
Liver (g) |
6.060 ± 0.301 |
5.628* ± 0.319 |
5.790 ± 0.516 |
5.383** ± 0.343 |
5.646* ± 0.432 |
Liver (%) |
3.17 ± 0.17 |
3.09 ± 0.16 |
3.10 ± 0.19 |
2.94 ± 0.19 |
3.11 ± 0.19 |
Thymic region (g) |
0.267 ± 0.029 |
0.238 ± 0.044 |
0.226* ± 0.042 |
0.225* ± 0.031 |
0.224* ± 0.045 |
Thymic region (%) |
0.14 ± 0.02 |
0.13 ± 0.02 |
0.12 ± 0.03 |
0.12 ± 0.02 |
0.12 ± 0.02 |
(a) Mean ± standard deviation for n =10,
(b) Percentage of body weight,
* p<0.05 compared to control,
** p<0.01 compared to controlEndpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEC
- 5 mg/m³
- Study duration:
- subchronic
- Species:
- rat
- Quality of whole database:
- high
Repeated dose toxicity: dermal - systemic effects
Link to relevant study records
- Endpoint:
- sub-chronic toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- Dec 16, 1985 – May 7, 1986
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP conform study according to OECD guideline.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 411 (Subchronic Dermal Toxicity: 90-Day Study)
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- no
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- SOURCE:
- Age at study initiation: 7 weeks
- Weight at study initiation: Males 219.8 – 277.4g; females 152.7 – 197.2g
- Fasting period before study: None
- Housing: Singly in stainless steel cages with solid sides and wire mesh floors
- Diet: ad linitum, ground Purina Certified Rodent Chow #5002
- Water: ad libitum
- Acclimation period: 3 weeks
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 + 3 °C
- Humidity (%): 30 – 70%
- Air changes (per hr): 20 – 30/hr
- Photoperiod (hrs dark / hrs light): 12 light/12 dark - Type of coverage:
- occlusive
- Vehicle:
- unchanged (no vehicle)
- Details on exposure:
- TEST SITE
- Area of exposure: 2x2 inches (1 inch = 2.54 cm)
- % coverage: approximately 10% of body surface
- Type of wrap if used: Coban Action Wrap secured with Scotchrap Veterninary Elastic Tape
- Time intervals for shavings or clipplings: Not specified
REMOVAL OF TEST SUBSTANCE
- Washing (if done): No, wiped clean
- Time after start of exposure: 6 hours
TEST MATERIAL
- Amount(s) applied (volume or weight with unit): applied neat ranging from 100 – 1000 mg/kg body weight
- Concentration (if solution): not applicable
- Constant volume or concentration used: not applicable
- For solids, paste formed: no
VEHICLE
- Justification for use and choice of vehicle (if other than water): not applicable
USE OF RESTRAINERS FOR PREVENTING INGESTION: No - Analytical verification of doses or concentrations:
- no
- Details on analytical verification of doses or concentrations:
- Verification of starting purity. Was applied neat.
- Duration of treatment / exposure:
- 13 weeks
- Frequency of treatment:
- 5 days/week
- Remarks:
- Doses / Concentrations:
0, 100, 300, 1000 mg/kg
Basis:
no data - No. of animals per sex per dose:
- 10/sex/dose with a satellite group of an additional 10/sex for the control and high dose
- Control animals:
- yes, concurrent no treatment
- Details on study design:
- - Dose selection rationale: Tested to limit dose
- Rationale for animal assignment (if not random): random
- Rationale for selecting satellite groups: random
- Post-exposure recovery period in satellite groups: 4 weeks - Positive control:
- None
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: twice daily for mortality and general clinical signs
- Cage side observations checked in table were included.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: weekly
DERMAL IRRITATION (if dermal study): No, other than gross observations
- Time schedule for examinations:
BODY WEIGHT: Yes
- Time schedule for examinations: weekly
FOOD CONSUMPTION: Yes
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
FOOD EFFICIENCY: No
WATER CONSUMPTION: No
OPHTHALMOSCOPIC EXAMINATION: Yes
- Time schedule for examinations: Pre-dose and post-dosing
- Dose groups that were examined: all
HAEMATOLOGY: Yes
- Time schedule for collection of blood: pre-dose, 4 weeks and 13 weeks
- Anaesthetic used for blood collection: No data
- Animals fasted: Yes
- How many animals: 10/sex/group pre-dose and 5/sex/group during dosing periods
- Parameters checked in table were examined: Leukocyte and erythrocyte count, hemoglobin, hematocrit, MCV, MCH, MCHC, platelet count, differential leukocyte count
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: pre-dose, 4 weeks and 13 weeks
- Animals fasted: Yes
- How many animals: 10/sex/group pre-dose and 5/sex/group during dosing periods
- Parameters checked in table were examined: Fasted glucose, urea nitrogen, creatinine, AST, ALT, total protein, albumin, total bilirubin, direct bilirubin, calcium, phosphorus, sodium, potassium, chloride
URINALYSIS: Yes
- Time schedule for collection of urine: Pre-dose, week 4 and week 13
- Metabolism cages used for collection of urine: Yes
- Animals fasted: Yes
- Parameters checked in table were examined: pH, protein, glucose, ketone, color, volume, bilirubin, blood, urobilinogen, specific gravity, turbidity
NEUROBEHAVIOURAL EXAMINATION: No
- Time schedule for examinations:
- Dose groups that were examined:
- Battery of functions tested: sensory activity / grip strength / motor activity / other: - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
HISTOPATHOLOGY: Yes - Statistics:
- Yes. Food consumption, body and organ weight were intercompared for the dose groups and control group by Levene’s test for homogeneity of variances, analysis of variance and individual t-tests (if significance in the analysis of variance).
- Clinical signs:
- no effects observed
- Dermal irritation:
- effects observed, treatment-related
- Description (incidence and severity):
- Excortiated skin and papules in treatment area of high dose male and female animals. This effect was also observed in the control animals and would appear to have been exacerbated by treatment but not caused by treatment.
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- no effects observed
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- not specified
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- no effects observed
- Dose descriptor:
- NOEL
- Effect level:
- 300 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Excoriated skin and papules at 1000 mg/kg.
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Critical effects observed:
- not specified
- Conclusions:
- Naphthalene has no effect on toxicity in rats when applied dermally for 13 weeks.
- Executive summary:
Male and female Sprague-Dawley CD® rats were exposed to naphthalene via the dermal route at 0, 100, 300, and 1000 mg/kg body weight/day. The test material was applied under occlusion for 6 hours per day, 5 days per week for 13 weeks. Following the exposure period, animals from each of the control and high dose groups were followed for 4 weeks during a recovery phase. No treatment-related effects on the incidence of clinical observations, ophthalmological changes, gross anatomic alterations, or histopathologic changes were observed. Cutaneous exposure to naphthalene did not affect food consumption, body weight, or clinical measurements conducted for clinical chemistry, haematology, and urinalysis parameters. Testes weights in the high dose group were slightly reduced at the 13-week sacrifice. However, this change was not noted at the 17-week recovery sacrifice. No other organ weight changes were observed. The decreased testes weight was considered to be of negligible biological significance based on the small magnitude of the change and the absence of any corroborating evidence of tissue alteration upon histologic examination. Based on the results of this study, cutaneous exposure of rats to crystalline naphthalene at or below 1000 mg/kg body weight/day is not considered to result in any biologically significant responses. The no observable effect level (NOEL) is considered to be at least 300 mg/kg body weight/day.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 1 000 mg/kg bw/day
- Study duration:
- subchronic
- Species:
- rat
- Quality of whole database:
- high
Repeated dose toxicity: dermal - local effects
Link to relevant study records
- Endpoint:
- sub-chronic toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- Dec 16, 1985 – May 7, 1986
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP conform study according to OECD guideline.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 411 (Subchronic Dermal Toxicity: 90-Day Study)
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- no
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- SOURCE:
- Age at study initiation: 7 weeks
- Weight at study initiation: Males 219.8 – 277.4g; females 152.7 – 197.2g
- Fasting period before study: None
- Housing: Singly in stainless steel cages with solid sides and wire mesh floors
- Diet: ad linitum, ground Purina Certified Rodent Chow #5002
- Water: ad libitum
- Acclimation period: 3 weeks
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 + 3 °C
- Humidity (%): 30 – 70%
- Air changes (per hr): 20 – 30/hr
- Photoperiod (hrs dark / hrs light): 12 light/12 dark - Type of coverage:
- occlusive
- Vehicle:
- unchanged (no vehicle)
- Details on exposure:
- TEST SITE
- Area of exposure: 2x2 inches (1 inch = 2.54 cm)
- % coverage: approximately 10% of body surface
- Type of wrap if used: Coban Action Wrap secured with Scotchrap Veterninary Elastic Tape
- Time intervals for shavings or clipplings: Not specified
REMOVAL OF TEST SUBSTANCE
- Washing (if done): No, wiped clean
- Time after start of exposure: 6 hours
TEST MATERIAL
- Amount(s) applied (volume or weight with unit): applied neat ranging from 100 – 1000 mg/kg body weight
- Concentration (if solution): not applicable
- Constant volume or concentration used: not applicable
- For solids, paste formed: no
VEHICLE
- Justification for use and choice of vehicle (if other than water): not applicable
USE OF RESTRAINERS FOR PREVENTING INGESTION: No - Analytical verification of doses or concentrations:
- no
- Details on analytical verification of doses or concentrations:
- Verification of starting purity. Was applied neat.
- Duration of treatment / exposure:
- 13 weeks
- Frequency of treatment:
- 5 days/week
- Remarks:
- Doses / Concentrations:
0, 100, 300, 1000 mg/kg
Basis:
no data - No. of animals per sex per dose:
- 10/sex/dose with a satellite group of an additional 10/sex for the control and high dose
- Control animals:
- yes, concurrent no treatment
- Details on study design:
- - Dose selection rationale: Tested to limit dose
- Rationale for animal assignment (if not random): random
- Rationale for selecting satellite groups: random
- Post-exposure recovery period in satellite groups: 4 weeks - Positive control:
- None
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: twice daily for mortality and general clinical signs
- Cage side observations checked in table were included.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: weekly
DERMAL IRRITATION (if dermal study): No, other than gross observations
- Time schedule for examinations:
BODY WEIGHT: Yes
- Time schedule for examinations: weekly
FOOD CONSUMPTION: Yes
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
FOOD EFFICIENCY: No
WATER CONSUMPTION: No
OPHTHALMOSCOPIC EXAMINATION: Yes
- Time schedule for examinations: Pre-dose and post-dosing
- Dose groups that were examined: all
HAEMATOLOGY: Yes
- Time schedule for collection of blood: pre-dose, 4 weeks and 13 weeks
- Anaesthetic used for blood collection: No data
- Animals fasted: Yes
- How many animals: 10/sex/group pre-dose and 5/sex/group during dosing periods
- Parameters checked in table were examined: Leukocyte and erythrocyte count, hemoglobin, hematocrit, MCV, MCH, MCHC, platelet count, differential leukocyte count
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: pre-dose, 4 weeks and 13 weeks
- Animals fasted: Yes
- How many animals: 10/sex/group pre-dose and 5/sex/group during dosing periods
- Parameters checked in table were examined: Fasted glucose, urea nitrogen, creatinine, AST, ALT, total protein, albumin, total bilirubin, direct bilirubin, calcium, phosphorus, sodium, potassium, chloride
URINALYSIS: Yes
- Time schedule for collection of urine: Pre-dose, week 4 and week 13
- Metabolism cages used for collection of urine: Yes
- Animals fasted: Yes
- Parameters checked in table were examined: pH, protein, glucose, ketone, color, volume, bilirubin, blood, urobilinogen, specific gravity, turbidity
NEUROBEHAVIOURAL EXAMINATION: No
- Time schedule for examinations:
- Dose groups that were examined:
- Battery of functions tested: sensory activity / grip strength / motor activity / other: - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
HISTOPATHOLOGY: Yes - Statistics:
- Yes. Food consumption, body and organ weight were intercompared for the dose groups and control group by Levene’s test for homogeneity of variances, analysis of variance and individual t-tests (if significance in the analysis of variance).
- Clinical signs:
- no effects observed
- Dermal irritation:
- effects observed, treatment-related
- Description (incidence and severity):
- Excortiated skin and papules in treatment area of high dose male and female animals. This effect was also observed in the control animals and would appear to have been exacerbated by treatment but not caused by treatment.
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- no effects observed
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- not specified
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- no effects observed
- Dose descriptor:
- NOEL
- Effect level:
- 300 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Excoriated skin and papules at 1000 mg/kg.
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Critical effects observed:
- not specified
- Conclusions:
- Naphthalene has no effect on toxicity in rats when applied dermally for 13 weeks.
- Executive summary:
Male and female Sprague-Dawley CD® rats were exposed to naphthalene via the dermal route at 0, 100, 300, and 1000 mg/kg body weight/day. The test material was applied under occlusion for 6 hours per day, 5 days per week for 13 weeks. Following the exposure period, animals from each of the control and high dose groups were followed for 4 weeks during a recovery phase. No treatment-related effects on the incidence of clinical observations, ophthalmological changes, gross anatomic alterations, or histopathologic changes were observed. Cutaneous exposure to naphthalene did not affect food consumption, body weight, or clinical measurements conducted for clinical chemistry, haematology, and urinalysis parameters. Testes weights in the high dose group were slightly reduced at the 13-week sacrifice. However, this change was not noted at the 17-week recovery sacrifice. No other organ weight changes were observed. The decreased testes weight was considered to be of negligible biological significance based on the small magnitude of the change and the absence of any corroborating evidence of tissue alteration upon histologic examination. Based on the results of this study, cutaneous exposure of rats to crystalline naphthalene at or below 1000 mg/kg body weight/day is not considered to result in any biologically significant responses. The no observable effect level (NOEL) is considered to be at least 300 mg/kg body weight/day.
Reference
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 4 mg/cm²
- Study duration:
- subchronic
- Species:
- rat
- Quality of whole database:
- high: area-specific dose not available, calculated from the highest dose of 300 mg/kg bw/d on a site of approx. 75 cm2/kg bw
Additional information
There are no verifiable epidemiological studies on the human health effects of naphthalene, and the only human information available derives from a limited number of early case-reports which provide no quantitative data on the levels or duration of exposure. A principal human health effect is haemolytic anaemia which in some cases reached marked severity in humans exposed by inhalation to naphthalene vapour and by ingestion of solid naphthalene. Dermal exposure to the solid and vapour was also likely in these cases.
Animal studies reveal species differences in response to naphthalene. Haemolytic anaemia was noted in a dog following oral dosing of 220 mg/kg/day for 7 days, but not in rodents even with high/prolonged exposures. Cataract formation was the principal effect seen in pigmented rats and rabbits following oral exposure to 700 and 1000 mg/kg/day, respectively, in studies ranging from 10-180 days, but this effect was not seen in mice with similar exposures. The lack of reliable reports of cataracts in humans despite the widespread use of naphthalene and accidental exposure to high doses suggests that cataract formation is unlikely to be a significant health effect in humans.
Very minor signs of nasal olfactory inflammation, not yet considered adverse, were reported in a 28 -and a 90 day rat inhalation study at 5 mg/m3 (1 ppm) (Coombs et al. 1993a). More marked changes in the olfactory epithelium were noted in a 90-day rat inhalation study at the lowest exposure level of 10 mg/m3 (2 ppm) (Coombs et al. 1993). These nasal effects became more marked with increasing levels of naphthalene exposure (Dodd et al. 2012). In a 104-week carcinogenicity study in mice, signs of nasal, olfactory and pulmonary inflammation were noted at 50 mg/m3, the lowest exposure concentration used. A NOEC could not be identified for local respiratory effects in these studies, but 1 ppm (5 mg/m3) is considered as a NOAEC.
General signs of toxicity, including death, were reported in rats and rabbits orally dosed with 700 and 1000 mg/kg/day, respectively. It is apparent that mice are more susceptible to naphthalene than rats or rabbits following oral treatment.
No histopathologic changes were reported in two oral 90-d studies in rats and mice at a dose of 200 mg/kg/d each; however, clinical signs of discomfort and decrease in body-weight gain were noted at the lower dose of 100 mg/kg bw/d (BCL 1980a,b).
An LD50 of 354 mg/kg was estimated in female mice treated with naphthalene once daily by gavage for 8 consecutive days (Plasterer et al. 1985, not shown). The dose response curve appeared to be very steep, because no deaths occurred at 250 mg/kg/day, but all animals died with a dose of 500 mg/kg/day. In a different study with a 14-day dosing period, 10% of the males and 5% of the females died at a dose of 267 mg/kg/day, but none were affected by doses of 27 and 53 mg/kg/day (Shopp et al. 1984b). In an increasing dose study, male rats were treated with naphthalene at doses beginning at 100 mg/kg/day and raised the dose weekly to a final level of 750 mg/kg/day over 6 weeks. Doses were then kept constant for an additional 3 weeks. The animals tolerated 750 mg/kg/day with no mortalities (Germansky and Jamall 1988). No increase in mortality was observed in rats administered naphthalene at 41 mg/kg/day in a 2-year feeding study (Schmahl 1955). For systemic effects, a NOAEL of 133 mg/kg/day was identified in a 90-day oral mouse study (Shopp et al. 1984a).
In the 90-day rat inhalation study, there was no evidence of systemic toxicity at exposures up to 300 mg/m3, although a reduction in body weight gain of up to 43% associated with reduced food consumption was observed at this top dose (Coombs et al. 1993). By the dermal route, a NOAEL for systemic toxicity of 1000 mg/kg/day (the highest dose tested) was identified in a 90-day rat study.
Justification for selection of repeated dose toxicity via oral route - systemic effects endpoint:
Relevant and comprehensive 90d study by the oral route of exposure
Justification for selection of repeated dose toxicity inhalation - systemic effects endpoint:
relevant 90-d study by route of inhalation in synopsis with carcinogenicity (inhalation) and oral repeated-dose study (oral).
Justification for selection of repeated dose toxicity inhalation - local effects endpoint:
identifiable NOAEC
Justification for selection of repeated dose toxicity dermal - systemic effects endpoint:
Only valid study available, comprehensive guideline study
Justification for selection of repeated dose toxicity dermal - local effects endpoint:
The only valid study available, comprehensive guideline study
Repeated dose toxicity: inhalation - systemic effects (target organ) respiratory: nose
Justification for classification or non-classification
Naphthalene is already classified as Carc. Cat. 3; R40 and Xn; R22 (according to 67/548/EEC or 1999/45/EC) /
Carc. 2, H351, Suspected of causing cancer; Acute toxic 4, H302, Harmful if swallowed (according to CLP Regulation (EC) No 1272/2008). No further classification is required.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.